Sirona Biochem Corp (SBM) - Net Assets
Based on the latest financial reports, Sirona Biochem Corp (SBM) has net assets worth CA$-3.46 Million CAD (≈ $-2.51 Million USD) as of July 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$809.18K ≈ $585.35K USD) and total liabilities (CA$4.27 Million ≈ $3.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Sirona Biochem Corp to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-3.46 Million |
| % of Total Assets | -428.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | -214.7% |
| 10-Year Change | -240.28% |
| Growth Volatility | 388.16 |
Sirona Biochem Corp - Net Assets Trend (2011–2023)
This chart illustrates how Sirona Biochem Corp's net assets have evolved over time, based on quarterly financial data. Also explore how large is Sirona Biochem Corp's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Sirona Biochem Corp (2011–2023)
The table below shows the annual net assets of Sirona Biochem Corp from 2011 to 2023. For live valuation and market cap data, see Sirona Biochem Corp market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-10-31 | CA$-2.51 Million ≈ $-1.82 Million |
-1270.72% |
| 2022-10-31 | CA$214.51K ≈ $155.18K |
+321.12% |
| 2021-10-31 | CA$-97.02K ≈ $-70.18K |
-304.69% |
| 2020-10-31 | CA$47.40K ≈ $34.28K |
-97.84% |
| 2019-10-31 | CA$2.19 Million ≈ $1.58 Million |
+196.84% |
| 2018-10-31 | CA$-2.26 Million ≈ $-1.64 Million |
-10.80% |
| 2017-10-31 | CA$-2.04 Million ≈ $-1.48 Million |
-230.54% |
| 2016-10-31 | CA$1.56 Million ≈ $1.13 Million |
-27.17% |
| 2015-10-31 | CA$2.15 Million ≈ $1.55 Million |
+19.88% |
| 2014-10-31 | CA$1.79 Million ≈ $1.30 Million |
-16.63% |
| 2013-10-31 | CA$2.15 Million ≈ $1.55 Million |
+26.25% |
| 2012-10-31 | CA$1.70 Million ≈ $1.23 Million |
-37.55% |
| 2011-10-31 | CA$2.72 Million ≈ $1.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sirona Biochem Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3875976300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$41.39 Million | % |
| Total Equity | CA$-2.51 Million | 100.00% |
Sirona Biochem Corp Competitors by Market Cap
The table below lists competitors of Sirona Biochem Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Max Resource Corp
V:MAX
|
$11.24 Million |
|
Annexin Pharmaceuticals AB
ST:ANNX
|
$11.24 Million |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
$11.24 Million |
|
Energoinstal S.A.
WAR:ENI
|
$11.25 Million |
|
Biovie Inc
NASDAQ:BIVI
|
$11.23 Million |
|
Calibre
PA:ALWIN
|
$11.23 Million |
|
Superior Resources Ltd
AU:SPQ
|
$11.21 Million |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
$11.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sirona Biochem Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 214,515 to -2,511,365, a change of -2,725,880 (-1270.7%).
- Net loss of 2,543,190 reduced equity.
- Other factors decreased equity by 182,690.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.54 Million | -101.27% |
| Other Changes | CA$-182.69K | -7.27% |
| Total Change | CA$- | -1270.72% |
Book Value vs Market Value Analysis
This analysis compares Sirona Biochem Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-10-31 | CA$-0.01 | CA$0.06 | x |
| 2018-10-31 | CA$-0.01 | CA$0.06 | x |
| 2019-10-31 | CA$0.01 | CA$0.06 | x |
| 2020-10-31 | CA$0.00 | CA$0.06 | x |
| 2021-10-31 | CA$0.00 | CA$0.06 | x |
| 2022-10-31 | CA$0.00 | CA$0.06 | x |
| 2023-10-31 | CA$-0.01 | CA$0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sirona Biochem Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7312.43%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-887.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -92.63% | 0.00% | 0.00x | 1.27x | CA$-2.80 Million |
| 2012 | -175.48% | 0.00% | 0.00x | 1.57x | CA$-3.15 Million |
| 2013 | -124.35% | 0.00% | 0.00x | 1.56x | CA$-2.88 Million |
| 2014 | -196.93% | -1697.18% | 0.06x | 1.91x | CA$-3.70 Million |
| 2015 | -170.52% | -45777.34% | 0.00x | 1.93x | CA$-3.87 Million |
| 2016 | -190.30% | -825.18% | 0.12x | 2.00x | CA$-3.13 Million |
| 2017 | 0.00% | -81572.68% | 0.00x | 0.00x | CA$-4.26 Million |
| 2018 | 0.00% | -99.57% | 1.66x | 0.00x | CA$-1.05 Million |
| 2019 | -207.79% | -3351.61% | 0.03x | 1.94x | CA$-4.77 Million |
| 2020 | -8721.86% | -3910.40% | 0.05x | 45.09x | CA$-4.14 Million |
| 2021 | 0.00% | -860.50% | 0.21x | 0.00x | CA$-2.30 Million |
| 2022 | -1658.53% | -529.50% | 0.52x | 6.02x | CA$-3.58 Million |
| 2023 | 0.00% | -7312.43% | 0.03x | 0.00x | CA$-2.29 Million |
Industry Comparison
This section compares Sirona Biochem Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $24,209,535
- Average return on equity (ROE) among peers: -379.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sirona Biochem Corp (SBM) | CA$-3.46 Million | -92.63% | N/A | $11.23 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company … Read more